Payment overview · 2025
General Payments
$737.80
37 reported records · 18 companies
Healthcare provider profile · identity verified
Dawn Eileen Stoecker-Simon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1588641062
Verified facts
What the public records show
CMS Open Payments records show Dawn Eileen Stoecker-Simon, MD received $737.80 in general payments during 2025 across 37 reported records.
Novo Nordisk Inc accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.93 | 14.1% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.04 | 9.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $61.45 | 8.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.06 | 8.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $60.12 | 8.2% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.96 | 6.8% | 3 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $47.87 | 6.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.06 | 5.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.86 | 5.0% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.73 | 4.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.24 | 4.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $28.35 | 3.8% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.06 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.99 | 3.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.00 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.09 | 2.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.84 | 2.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.15 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $737.80 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $89.08 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.04 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $61.45 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.06 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $49.96 | 3 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $47.87 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.24 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.79 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $28.35 | 2 | 2025 |
Source payment records
|
|||||
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.99 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.09 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 128 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
200 | 53 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
128 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
80 | 77 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 412 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 92 |
| Gabapentin | Gabapentin | 213 | 61 |
| Azithromycin | Azithromycin | 203 | 156 |
| Synthroid | Levothyroxine Sodium | 200 | 53 |
| Losartan Potassium | Losartan Potassium | 186 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 183 | 50 |
| Valsartan | Valsartan | 177 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 56 |
| Alprazolam | Alprazolam | 164 | 39 |
| Omeprazole | Omeprazole | 152 | 45 |
| Sertraline Hcl | Sertraline Hcl | 149 | 33 |
| Methylprednisolone | Methylprednisolone | 147 | 105 |
| Potassium Chloride | Potassium Chloride | 137 | 40 |
| Glipizide Er | Glipizide | 131 | 35 |
| Simvastatin | Simvastatin | 129 | 36 |
| Trazodone Hcl | Trazodone Hcl | 129 | 39 |
| Eliquis | Apixaban | 128 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 122 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 30 |
| Montelukast Sodium | Montelukast Sodium | 120 | 36 |
| Lisinopril | Lisinopril | 116 | 41 |
| Meloxicam | Meloxicam | 114 | 44 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 108 | 81 |
| Ozempic | Semaglutide | 108 | 21 |
| Bupropion Xl | Bupropion Hcl | 107 | 27 |
| Metformin Hcl Er | Metformin Hcl | 107 | 34 |
| Lorazepam | Lorazepam | 97 | 27 |
| Carvedilol | Carvedilol | 95 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 28 |
| Prednisone | Prednisone | 94 | 57 |
| Spironolactone | Spironolactone | 94 | 23 |
| Furosemide | Furosemide | 92 | 33 |
| Tramadol Hcl | Tramadol Hcl | 90 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 27 |
| Ezetimibe | Ezetimibe | 86 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 80 | 62 |
| Paxlovid | Nirmatrelvir/Ritonavir | 80 | 77 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 15 |
| Cefdinir | Cefdinir | 72 | 60 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 25 |
| Irbesartan | Irbesartan | 71 | 18 |
| Clonazepam | Clonazepam | 70 | 20 |
| Valacyclovir | Valacyclovir Hcl | 66 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 33 |
| Nifedipine Er | Nifedipine | 63 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 20 |
| Celecoxib | Celecoxib | 60 | 16 |
| Ondansetron Odt | Ondansetron | 60 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 44 |
| Estradiol | Estradiol | 56 | 19 |
| Memantine Hcl | Memantine Hcl | 56 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 55 | 18 |
| Mirtazapine | Mirtazapine | 54 | 17 |
| Rizatriptan | Rizatriptan Benzoate | 54 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 15 |
| Metformin Hcl | Metformin Hcl | 53 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 38 |
| Eszopiclone | Eszopiclone | 49 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | 14 |
| Temazepam | Temazepam | 43 | 16 |
| Pregabalin | Pregabalin | 42 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 40 | 28 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 11 |
| Diazepam | Diazepam | 39 | 13 |
| Mupirocin | Mupirocin | 39 | 29 |
| Allopurinol | Allopurinol | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 28 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Torsemide | Torsemide | 35 | 11 |
| Bumetanide | Bumetanide | 33 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Minoxidil | Minoxidil | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 18 |
| Ramipril | Ramipril | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 18 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Famotidine | Famotidine | 21 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Zaleplon | Zaleplon | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 15 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Acetazolamide | Acetazolamide | 12 | 12 |
| Acyclovir | Acyclovir | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $737.80 · 37 records | Novo Nordisk Inc | AIRSUPRA, ALVESCO, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, GARDASIL 9, Heplisav-B, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Tymlos, UBRELVY, UNITHROID, Wegovy, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error